Alcon (ALC) announced the U.S. launch of SYSTANE PRO Preservative-Free PF as the latest over-the-counter eye drop in the company’s dry eye ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader ... as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye ...

Alcon (SIX/NYSE: ALC), the global leader in ... as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE ...

Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter ...

the EX-PRESS ® Glaucoma Filtration Device and pharmaceutical drops. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years ...

ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.

Due to its progressive nature, early intervention and a variety of treatment options—from drops to surgical intervention—is critical to preserve sight. 5 Notable medical societies, including ...

Alcon forecast sales of between $10.2 and $10.4 billion for 2025, in line with market expectations, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division ...

Alcon’s advanced lenses, including toric and multi-focal modalities, continue to gain market share. Ocular Health continues to report strong performance with its portfolio of eye drops, including ...

Alcon’s ALC Surgical business continues to gain from its diverse portfolio and incremental innovation. Within Vision Care, the company is registering solid growth, banking on strong sales of its ...